Hemogenyx Pharmaceuticals PLC Stmnt re Share Price Movement (9527F)
2018年2月26日 - 11:17PM
RNSを含む英国規制内ニュース (英語)
TIDMHEMO
RNS Number : 9527F
Hemogenyx Pharmaceuticals PLC
26 February 2018
The information contained within this announcement is deemed to
constitute inside information as stipulated under the Market Abuse
Regulation (EU) No. 596/2014. Upon the publication of this
announcement, this inside information is now considered to be in
the public domain.
Hemogenyx Pharmaceuticals Plc
("Hemogenyx" or the "Company")
Statement re. Share Price Movement
Lead candidate shown to be effective in treatment of
Leukemia
Hemogenyx Pharmaceuticals Plc (LSE: HEMO), the biotechnology
company developing novel therapies to transform bone marrow, or
blood stem cell, transplantation for the treatment of blood
diseases, notes the recent share movement in the Company's share
price in reaction to a premature disclosure which the company
regrets and is not in accordance with the Company's policies on the
release of information.
The Company can confirm that it has filed a provisional patent
application relating to the Company's development of a new type of
humanised mice with a chimeric mouse-human blood system that can be
used to advance product development, as well as for other disease
modelling and drug development.
First data results have shown that CDX bi-specific antibodies
are capable of attacking and eliminating the blood cancer Acute
Myelogenous Leukemia (AML) in vitro. Using these new humanised mice
the Company is confident that it should be able to demonstrate that
its lead product, CDX bi-specific antibodies, are effective in the
treatment of (AML). Use of the humanised mouse model should
facilitate developing and progressing the CDX bi-specific
antibodies into human trials, in line with the Company's
development timeline.
AML affected about one million people globally in 2015 and
resulted in 147,000 deaths. AML accounts for roughly 1.8% of cancer
deaths in the United States with about 20,000 new cases diagnosed
in the US and 18,000 cases in Europe every year.
Despite numerous advances in understanding of the biology and
pathogenesis of AML, standard treatments remain unsatisfactory and
initial treatment relies on intensive chemotherapy. Current
transplantation treatments for patients with chemosensitive forms
of the disease have only a 30% success rate, but many, often older,
patients will not be healthy enough even to undergo such
treatments. CDX bi-specific antibodies, will redirect a patient's
own immune cells to eliminate both AML and blood stem cells
preparing a patient with relapsed/refractory AML for bone marrow
transplantation. Directors believe that this product could replace
traditional methods of treatment of relapsed/refractory AML and
conditioning such as chemotherapy and radiation.
Dr Vladislav Sandler, CEO & Co-Founder of Hemogenyx,
commented: "We are hugely excited by the first solid data that
we've received testing the efficacy of CDX antibodies against Acute
Myelogenous Leukemia. The results which show that they can attack
and eliminate AML cells is a true breakthrough and a significant
development in our process of developing CDX to become a
universally available conditioning product for patients undergoing
bone marrow transplants as a treatment for serious blood
diseases.
"In addition the new type of humanised mice opens the door to
extending our work into other disease models and specific drug
development which we expect to be of great interest to large
biopharmaceutical companies and could form the basis of a number of
significant future collaborations."
Enquiries:
Hemogenyx Pharmaceuticals Limited www.hemogenyx.com
Dr Vladislav Sandler, Chief Via Walbrook PR
Executive Officer & Co-Founder
Dr Robin Campbell, Chairman
Optiva Securities Ltd Tel: +44 (0)20 3137 1902
Christian Dennis
Shard Capital Partners LLP Tel: +44 (0)20 7186 9950
Damon Heath, Erik Woolgar
Peterhouse Corporate Finance Tel: +44 (0)20 7469 0930
Limited
Lucy Williams/Duncan Vasey
Walbrook PR (UK Media & Tel: +44 (0)20 7933 8780 or
Investor Relations) hemogenyx@walbrookpr.com
Paul McManus Mob: +44 (0)7980 541 893
US Media enquiries
Lowell Goodman Tel: +1 (323) 646-3249 or lowell@lowellgoodman.net
About Hemogenyx Pharmaceuticals Plc
Hemogenyx Pharmaceuticals Plc is a publicly traded company (LSE:
HEMO) headquartered in London, with its wholly owned U.S. operating
subsidiary, HemoGenyx LLC, located in its state-of-the-art research
facility in Brooklyn, New York.
HemoGenyx is a preclinical-stage biopharmaceutical company
focused on the discovery, development and commercialization of
novel therapies and treatments for blood diseases such as leukemia
and lymphoma. The company's leading technologies aim to change the
way in which bone marrow/hematopoietic stem cell (BM/HSC)
transplants are performed and improve their efficacy. HemoGenyx's
two distinct and complementary products include an immunotherapy
product for patient conditioning-the CDX bi-specific antibody-and a
cell therapy product for BM/HSC transplantation-the HuPHEC. Each of
these products holds the potential to revolutionize the way BM/HSC
transplants are being performed, offering solutions that mitigate
the dangers and limitations associated with the current standard of
care.
For more information, visit www.hemogenyx.com.
This information is provided by RNS
The company news service from the London Stock Exchange
END
SPMEALAKAFSPEFF
(END) Dow Jones Newswires
February 26, 2018 09:17 ET (14:17 GMT)
Hemogenyx Pharmaceuticals (LSE:HEMO)
過去 株価チャート
から 6 2024 まで 7 2024
Hemogenyx Pharmaceuticals (LSE:HEMO)
過去 株価チャート
から 7 2023 まで 7 2024